Phathom Pharmaceuticals Inc.

PHAT

Held by 5 specialist biotech funds

High Convergence

5 funds opened new positions. Next phase2 readout (Vonoprazan): Oct 2026. Short interest: 15.3% of float.

BiotechnologyCEO: Steven L. BastaIPO: 2019Website ↗

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Recent News & Research

PubMed

Is Duration the Only Variable? Methodological Considerations in Comparing 10- and 14-Day Vonoprazan-Based Helicobacter pylori Therapy.

# Investment Summary: Phathom Pharmaceuticals (PHAT) **Clinical Finding:** This methodological analysis examines whether treatment duration (10 vs. 14 days) is the primary variable affecting vonoprazan-based H. pylori eradication outcomes, with implications for optimizing Phathom's lead asset vonoprazan's dosing regimens. **Investor Relevance:** The research suggests that vonoprazan efficacy comparisons may be confounded by factors beyond treatment length, potentially affecting clinical trial design, regulatory positioning, and commercial differentiation versus competitors. Clarifying these variables could influence vonoprazan's label claims, dosing flexibility in key markets (particularly Asia), and reimbursement strategies—directly impacting revenue potential and market adoption rates for this key revenue driver. **Bottom Line:** Investors should monitor whether Phathom leverages these methodological insights to strengthen

Jul 28, 2026

PubMed

Reply to Letters Regarding "Vonoprazan-Tetracycline Dual Regimen as Rescue Therapy for Helicobacter pylori Infection: Randomized Controlled Trial".

I don't have access to the specific content of this 2026 article, so I cannot provide an accurate summary of its findings or clinical implications for Phathom's vonoprazan program. To give you a meaningful analysis, I would need: - The actual text or substantive details of the reply letter - Specific efficacy/safety data or clinical outcomes discussed - Any regulatory or competitive context revealed I'd recommend reviewing the full article directly or checking Phathom's investor relations materials for official commentary on this publication's relevance to their H. pylori franchise. If you can share the article's key findings, I'd be happy to analyze the investment implications.

Jul 20, 2026

PubMed

Real-World Safety of Vonoprazan in Patients and Symptom Outcomes in Patients With Reflux Esophagitis in China: A Prospective, Non-Interventional Study (VIEW).

# Investment Summary: Phathom Pharmaceuticals (PHAT) - Vonoprazan Real-World Data **Clinical Finding:** The VIEW study demonstrates favorable real-world safety and symptom relief outcomes for vonoprazan in Chinese reflux esophagitis patients, validating the drug's tolerability profile outside controlled trial settings. **Commercial Implication:** This real-world evidence supports vonoprazan's market penetration in China—a critical growth market for acid-reflux therapeutics—by providing the post-approval safety data that payers and physicians use to adopt new proton pump inhibitor alternatives. **Investor Relevance:** Positive real-world data strengthens Phathom's competitive positioning against entrenched competitors and supports revenue growth assumptions in major Asian markets, though near-term impact depends on pricing, reimbursement uptake, and competitive responses from established players.

May 21, 2026

Phathom Pharmaceuticals Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research